[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578146":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":30,"locations":39,"responsibleParty":62,"collaborators":64,"id":68,"slug":29,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":29,"enrollmentInfo":77,"targetDuration":29,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":42,"whyStopped":29,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"ScreenCell","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Donor","ACTIVE_COMPARATOR","Participants with no prior history of cancer and confirmed to be cancer-free at the time of inclusion, as evidenced by a negative mammogram performed within two years before enrollment",[13],"Device: The DM\u002FDIV ScreenCell is the experimental product studied during this research",{"label":15,"type":16,"description":17,"interventionNames":18},"Metastatic","EXPERIMENTAL","Participants with metastatic breast cancer or metastatic relapse of previously treated breast cancer with change of therapeutic line at the time of study inclusion, confirmed by a POSITIVE PET-Scan",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"No metastatic","Participants with invasive breast cancer but non-metastatic, confirmed by PET scan or mammography (confirmation not mandatory)",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DEVICE","The DM\u002FDIV ScreenCell is the experimental product studied during this research","The product is not used directly on the subject, but on a blood sample taken from the participant.",[9,15,20],null,[31,36],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Jessica GROULT, Ph.D","CONTACT","0033669645318","jgroult@screencell.com",{"name":37,"role":33,"phone":29,"phoneExt":29,"email":38},"Sina NASERIAN, Ph.D","snaserian@screencell.com",[40],{"facility":41,"status":42,"city":43,"state":29,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"CMC Ambroise Paré Hartmann","RECRUITING","Neuilly-sur-Seine","92200","France","FR",{"type":48,"coordinates":49},"Point",[50,51],2.26965,48.8846,{"lat":51,"lon":50},[54,57,60],{"name":55,"role":56,"phone":29,"phoneExt":29,"email":29},"Jean-Michel VANNETZEL, M.D.","PRINCIPAL_INVESTIGATOR",{"name":58,"role":59,"phone":29,"phoneExt":29,"email":29},"Jean-François LLORY, M.D.","SUB_INVESTIGATOR",{"name":61,"role":59,"phone":29,"phoneExt":29,"email":29},"Marie-Laure CHABI, M.D.",{"type":63,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[65],{"name":66,"class":67},"AXELYS SANTE","UNKNOWN","100578146",false,"NCT06807502","Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device","PROBE-CTC","INCLUSION CRITERIA\n\nFor all participants :\n\n* Female with age greater than or equal to 18 years\n\nFor participants with metastatic breast cancer:\n\n\\- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion.\n\nFor participants with non-metastatic invasive breast cancer:\n\n\\- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment)\n\nFor healthy volunteers:\n\n* Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion\n* Participant with no history of cancer\n\nEXCLUSION CRITERIA\n\nFor all participants:\n\n* Male\n* Age less than 18 years old\n* Refusal to participate or withdrawal of consent\n* Pregnant and\u002For breastfeeding women\n* Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up.\n\nFor healthy volunteers:\n\n* History of cancer\n* Detection of CTC (positive profile) during screening",true,"FEMALE","18 Years",{"count":78,"type":79},93,"ESTIMATED","INTERVENTIONAL",[82],"NA","Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.\n\nThe identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up",[85,86,87],"Breast Cancer, Metastatic","Breast Cancer Invasive","Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[89,90,91,92,93,94,95],"CTC","Circulating Tumor Cells","Detection","Breast Cancer","Follow-up","Liquid Biopsy","Blood Test","2026-04-21",{"date":98,"type":99},"2026-04-24","ACTUAL",{"date":101,"type":99},"2025-02-24",{"date":103,"type":79},"2026-11-30",{"name":5,"class":6},1]